Compare Mesoblast Limited (MESO) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Rigetti Computing Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Rigetti Computing Inc trades at $14.75 (market cap $4.74B). The key difference: Rigetti Computing Inc is far larger — about 2.2× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| MESO | RGTI | |
|---|---|---|
Market Cap | $2.17B | $4.74B |
Sector | Technology | Technology |
52-Week High | $20.96 | $56.34 |
52-Week Low | $12.88 | $12.90 |
Enterprise Value | $2.17B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with a net income margin of -2,253.59% and negative cash flow from operations of $58.54M in 2025. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly bullish with an average price target of $32.67, representing 129% upside potential from current levels.
While RGTI faces substantial execution risks in the pre-commercial quantum computing space, its government contracts and technological positioning offer long-term potential. Investors should weigh the company's speculative nature against analyst optimism and the emerging quantum computing market opportunity, with careful attention to cash burn and commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
